Latest News & Features
Biotechnology
Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains. 19 February 2014
Big Pharma
Common themes, in particular in the context of second medical use claims and dosage regimes, are on the radar of the UK courts, as Jennifer Antcliff and Dennis Waller report. 19 February 2014
Americas
The US Supreme Court has again reversed a Federal Circuit decision, this time over burden of proof, says Matthew Nielsen. 19 February 2014
Big Pharma
The CJEU has delivered its judgment in three SPC cases, in an attempt to address fundamental issues in the SPC Regulation, as well as uncertainties arising from earlier rulings. Although questions have been answered, others have been raised, say David Carling and Michael Pears. 19 February 2014
Americas
In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level. 3 February 2014
article
Susana Soares is a designer inspired by scientific research to create objects that explore new aesthetic and behavioural opportunities. LSIPR investigated how she protects her work in a realm where life sciences and design collide. 3 February 2014
Americas
Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field. 13 January 2014
Big Pharma
Three December decisions from the Court Of Justice of the European Union shed light on supplementary protection certificates in Europe. 13 January 2014
Americas
How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande. 3 December 2013
Asia-Pacific
As the largest science research institute in Japan, Riken has an important role in promoting innovation. LSIPR talked to Akihiro Fujita, director of the institute’s research cluster for innovation, about the place of intellectual property in that endeavour. 3 December 2013